ESSA Pharma Inc (EPIX)
1.66
+0.01
(+0.61%)
USD |
NASDAQ |
May 21, 16:00
1.67
+0.01
(+0.60%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 73.69M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -73.23% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 0.6489 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 98.26% |
Profile
Edit
| ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies. |
| URL | https://www.essapharma.com |
| Investor Relations URL | https://investors.essapharma.com/ |
| HQ State/Province | British Columbia |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Aug. 05, 2025 (est.) |
| Last Earnings Release | May. 08, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
Edit
| ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies. |
| URL | https://www.essapharma.com |
| Investor Relations URL | https://investors.essapharma.com/ |
| HQ State/Province | British Columbia |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Aug. 05, 2025 (est.) |
| Last Earnings Release | May. 08, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |